Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update
Open Access
- 13 May 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (5) , 875
Abstract
Cytomegalovirus (CMV) is one of the most important opportunistic infections in solid organ transplant (SOT) recipients. However, current techniques used to predict risk for CMV infection fall short. CMV-specific cell mediated immunity (CMI) plays an important role in protecting against CMV infection. There is evidence that assays measuring CMV-CMI might better identify SOT recipients at risk of complications from CMV compared to anti-CMV IgG, which is our current standard of care. Here, we review recently published studies that utilize CMV-CMI, at various points before and after transplantation, to help predict risk and guide the management of CMV infection following organ transplantation. The evidence supports the use of these novel assays to help identify SOT recipients at increased risk and highlights the need for larger prospective trials evaluating these modalities in this high-risk population.Keywords
This publication has 99 references indexed in Scilit:
- Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2013
- Pretransplant Interferon-γ Secretion by CMV-Specific CD8+ T Cells Informs the Risk of CMV Replication After TransplantationAmerican Journal of Transplantation, 2013
- Hemodialysis Affects Phenotype and Proliferation of CD4-Positive T LymphocytesJournal of Clinical Immunology, 2011
- Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2009
- Immunobiology of Human Cytomegalovirus: from Bench to BedsideClinical Microbiology Reviews, 2009
- Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipientsJournal of Translational Medicine, 2008
- Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patientsJournal of Clinical Virology, 2008
- Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal TransplantationAmerican Journal of Transplantation, 2008
- Prevention dof recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovirTransplant Infectious Disease, 2000
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992